Swiss National Bank
KNTE

Swiss National Bank’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Swiss National Bank’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-24,000
Closed -$270K – 2807
2022
Q1 		$270K Hold
24,000
– – ﹤0.01% 2664
2021
Q4 		$425K Hold
24,000
– – ﹤0.01% 2688
2021
Q3 		$552K Hold
24,000
– – ﹤0.01% 2572
2021
Q2 		$559K Buy
+24,000
New +$611K ﹤0.01% 2617

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Swiss National Bank's KNTE Position: Q2 2022 in Review

Swiss National Bank sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q2 2022, closing a stake of 24,000 shares — an estimated $270K sold.

Swiss National Bank first reported a position in KNTE in Q2 2021 and held it in 4 quarters. The position peaked at $559K in Q2 2021. 73 funds tracked by Wall St. Rank hold KNTE as of Q2 2022.

  • Swiss National Bank reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Swiss National Bank sold 24,000 Kinnate Biopharma Inc. Common Stock shares in Q2 2022, an estimated $270K.
  • Swiss National Bank first reported a position in Kinnate Biopharma Inc. Common Stock in Q2 2021 and held it in 4 quarters.
  • Swiss National Bank's Kinnate Biopharma Inc. Common Stock position peaked at $559K in Q2 2021.
  • 73 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q2 2022.

Based on Swiss National Bank's 13F filing for Q2 2022, filed 9 Aug 2022.